79results about How to "Improve in vitro dissolution" patented technology

The present invention relates to a method capable of using natural and artificial synthetic isosulfocyanate compound or its derivative to prevent and cure prostatic diseases and skin carcinoma. The internal tests show that various isosulfocyanate compounds or their derivatives can induce prostatic cell II phase drug metabolic detoxication enzyme-glutathione transferase so as to can inhibit the hyperplasia of prostate and inflammation, and can prevent and cure prostatic carcinoma and skin carcinoma.

The invention relates to oral double iguratimod controlled release formulation, which comprises fast release layer and slow release layer that are composed of 8-30% micronizing iguratimod crystal powder and medical findings, and the granule size of iguratimod crystal powder is 1-10 um. The effective component in fast release layer is released in short time and reaches to effective blood chemical concentration for effective action; the iguratimod in sloe release layer is released gradually and maintains effective blood medical concentration for continuous effective action. The invention overcomes shortcomings of short effective action time and a little high toxic effect.

A dispersed solid or orally taken composition of gliben clamide clamide is prepared from glibenclamide and dispersing medium proportionally through mixing, grinding and fusing or spray drying.

The invention relates to the field of medicines, in particular to a gefitinib tablet preparation method. The gefitinib tablet mainly comprises a main medicine and auxiliary materials. The gefitinib tablet preparation method is characterized in that the gefitinib particle diameter D90 is not more than 10 [mu]m, the proportion of lactose to microcrystalline cellulose is 1: (3-7), uniform mixing is performed according to the formula dosage, and then pelletizing, drying, granulating and tabletting are carried out. The prepared gefitinib tablet is stable in property, reliable in quality and high in bioavailability.

The invention relates to the field of medicinal preparations and particularly relates to a montelukast sodium chewable tablet, apreparation method and a determination method of a dissolution rate. Raw materials of the montelukast sodium chewable tablet comprise montelukast sodium, mannitol, microcrystalline cellulose, hydroxy propyl cellulose, crosslinking sodium carboxymethylcellulose, aspartame, ferric oxide, magnesium stearate and cherry essence. The hydroxy propyl cellulose is prepared into a solution with a mass percentage content being 6-8% through water being a solvent and a disintegrating agent is prepared through a wet process of an internal addition method. The montelukast sodium chewable tablet is significantly increased in disintegrating speed and in-vitro dissolution rate. By means of a dissolution curve detection method, quality differences among products in each batch can be effectively distinguished. Differences between products in each batch can be reduced better and a quality risk of the products can be controlled in a controllable range.

The invention relates to a hydrochloric acid dapoxetine tablet and belongs to the field of medicine production new technologies, in particular to the hydrochloric acid dapoxetine tablet and a preparation method thereof. Hydrochloric acid dapoxetine serves as the main constituent, and the tablet is obtained through direct tabletting of hydrochloric acid dapoxetine solid dispersion particles and auxiliary materials; a preparation method of the hydrochloric acid dapoxetine solid dispersion particles comprises the steps of mixing hydrochloric acid dapoxetine with organic solvent for forming a clear solution, and then adding the clear solution to dextrin for conducting pelleting. The weight ratio of hydrochloric acid dapoxetine and dextrin is 1 to 2-15, and the organic solvent is one or more out of ethanol, acetic acid, ethyl acetate and acetone. By means of the hydrochloric acid dapoxetine tablet, the influence of crystal form difference on preparations is eliminated, and the obtained hydrochloric acid dapoxetine tablet is good in in-vitro dissolution, safe and stable.

The invention belongs to the field of pharmaceutical preparations, and relates to a pharmaceutical composition for improving in-vitro dissolution and liquidity of spironolactone and a preparation method of the pharmaceutical composition. The pharmaceutical composition is mainly characterized by being prepared from an indissolvable drug spironolactone and a carrier material, wherein the mass ratio of the drug to the carrier is 1:3-1:10, the pharmaceutical composition prepared through a hot-melt extrusion technique is solid dispersion, the spironolactone is dispersed into the carrier in a molecular or amorphous mode, and therefore the in-vitro dissolution of the spironolactone is significantly improved. After the spironolactone is smashed, the liquidity of the spironolactone is significantly improved, and the smashed spironolactone can be directly filled into capsules or directly subpackaged by serving as powder and granules or used by being mixed with other pharmaceutical auxiliary materials to prepare tablets. Compared with traditional methods such as the solvent method and the solvent-melt method, the adopted hot-melt extrusion technique has the advantages of being capable of not using an organic solvent, safe, free of pollution, stable in technology, capable of achieving continuous operation, easily achieving industrialized enlarged production and improving the liquidity without needing to add a flow aid and the like.

The invention provides a probucol orally administered nanometer solid preparation, which comprises, by weight, 1 part of probucol, 0.01-0.1 part of additive and 0.05-0.4 part of auxiliary materials. The grain size of the probucol ranges from 10nm to 200nm. The invention further provides a preparation method for the probucol orally administered nanometer solid preparation. The preparation method includes that the probucol and water liquor with 5% of additive are prepared into nanometer suspension with the grain size ranging from 100nm to 600nm by a wet grinding method; the nanometer suspension is homogenized into nanometer grains with the grain sizes ranging from 10nm to 200nm by a high-pressure homogenizing machine; and the nanometer suspension which is homogenized is solidified and is added with the auxiliary materials to be prepared into the orally administered nanometer solid preparation. Compared with a common probucol tablet, the preparation has the advantages that dissolution in vitro of the preparation is increased by 20-30 times, and bioavailability after oral administration is improved by 10-20 times. In addition, the drug loading rate of the preparation is high, and the preparation can meet the requirements of tablet weight clinically needed by high-dose probucol administration. Besides, the preparation is stable, and the dissolution of the preparation can be kept unchanged within two years.

The invention discloses a preparation process capable of improving bioavailability of rabeprazole sodium enteric capsules. The rabeprazole sodium enteric capsules prepared by the invention are prepared from rabeprazole sodium enteric mini-pills and hard capsule shells, wherein each rabeprazole sodium enteric mini-pill comprises a drug-loaded pill core, an isolation layer and an enteric layer; each drug-loaded pill is prepared from rabeprazole sodium, mannitol, low substituted hydroxypropy cellulose, high substituted hydroxypropyl cellulose L, calcium hydroxide, sodium hydroxide, and tween 80. Each isolation layer is prepared from ethyl cellulose, high substituted hydroxypropyl cellulose L and magnesium stearate; the enteric layer is prepared from acrylic resin, triethyl citrate and talcum powder. According to the preparation process, the production efficiency of the rabeprazole sodium enteric capsules can be improved, the produced rabeprazole sodium enteric capsules are uniform in quality, good in stability and high in dissolution in vitro; moreover, the bioavailability of rabeprazole sodium enteric capsules can be obviously improved, and the rabeprazole sodium enteric capsules have good market prospect.

The invention relates to a solid dispersion of arctigenin and an oral solid preparation. The solid dispersion consists of the arctigenin and a carrier material, wherein the weight ratio of the arctigenin to the carrier material is 1:1-1:50. The defects of poor oral administration absorption and low bioavailability of the arctigenin are overcome, stability of the arctigenin is improved, objectionable odor and irritation of medicaments are concealed, and a preparation technology is simple and suitable for industrialized production.

The invention belongs to the field of pharmacy, and relates to a breviscapine composition nano-particle and a preparation method thereof. The provided novel breviscapine composition nano-particle is prepared by a solution containing the breviscapine, a polymer, a surfactant and a solvent with the adoption of an electrostatic spraying technology. The composition preparation device is simple, the parameters are controllable, the drug loading capacity is high, , the direct and continuous nano-particles with uniform particle size distribution can be obtained, the specific surface area is increased, and the dissolution in vitro and bioavailability of the breviscapine are improved remarkably.

The invention discloses a solid preparation containing [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, and the [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]- acetic acid in the solid preparation is a single crystal form with a particle size range of 3-65 [mu] m. The solid preparation also comprises one or more hydrophilic polymer materials as adhesives. The solid preparation disclosed by the invention is high in dissolution rate and bioavailability.

The invention belongs to the technical field of medicines and in particular relates to lacidipine-spirolactone co-amorphous solid dispersion and a preparation method thereof. According to the preparation method, lacidipine and spirolactone, which have a cooperative blood pressure lowering effect, are carriers for each other, and the co-amorphous solid dispersion is prepared by adopting a solvent volatilization method. The co-amorphous solid dispersion is formed by combining the lacidipine and the spirolactone according to the mol ratio of 1 to (1 to 9); Cu-Kalpha radiation is utilized, and a powder X-ray diffraction spectrum shown as a 2theta angle does not have a sharp diffraction peak; peak positions and peak strength of the co-amorphous solid dispersion are obviously changed in a Fourier infrared spectrum. Compared with a lacidipine crystal and a spirolactone crystal, the co-amorphous solid dispersion has the advantages that the dissolution rates and dissolvability of the lacidipineand the spirolactone are remarkably improved. The preparation method of the solid dispersion is simple and feasible and has good repeatability; amplified production is easy to carry out and industrial transformation is carried out; the preparation method has a good clinical application prospect.

The invention provides pharmaceutical composition for edoxaban tablets. The composition is prepared from 10-50 parts of p-toluenesulfonic acid edoxaban monohydrate, 15-35 parts of a disintegrant, 2-10parts of a 5% polyvinylpyrrolidone 95% ethanol solution, 20-45 parts of filler and 0.5-2 parts of a lubricant, and has the advantages of high disintegration speed, high bioavailability, good stability and the like.

The invention provides a penicillin medicine capsule, wherein a capsule shell containing hydroxypropyl starch can maintain the capsule to be stable and prevent the materials in the capsule shell from being wetted and penicillin from being degraded, thereby increasing in-vitro dissolubility and bioavailability of the capsule and further improving quality stability of the capsule.

The invention discloses curcumenol solid dispersion and an oral solid preparation thereof. The solid dispersion is composed of curcumenol and a carrier material, wherein a weight ratio of the curcumenol to the carrier material is 1:1 to 1:11. The oral solid preparation can be tablets, capsules or granules and has the advantages of low side effects, high bioavailability, high safety, small toxic and side effects, convenience in application and the like.